Physician profile
Stuart W White
NPI 1912990573
$10,283.62
in general payments reported to CMS, 2019-2025
30 companies · $1,352 in 2025
The $1,352 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,035 · 2020: $539 · 2021: $2,011 · 2022: $2,157 · 2023: $1,658 · 2024: $1,532 · 2025: $1,352.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,541.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,541.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $1,759.00 | 2019-2025 | Hizentra, Haegarda, Andembry |
| Astrazeneca Pharmaceuticals LP | $1,553.98 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Regeneron Healthcare Solutions, INC. | $1,392.58 | 2019-2025 | Dupixent |
| Glaxosmithkline, LLC. | $1,201.04 | 2019-2025 | Arexvy, Trelegy Ellipta, Nucala |
| Genzyme Corporation | $851.62 | 2020-2025 | |
| Pfizer INC. | $472.58 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $434.57 | 2020-2025 | Takhzyro, Hyqvia |
| Kaleo, INC. | $360.76 | 2019-2024 | Auvi-Q |
| Teva Pharmaceuticals USA, INC. | $316.26 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $254.26 | 2019-2022 | |
| Pharming Healthcare, INC. | $238.79 | 2021-2025 | Ruconest |
| Grifols USA, LLC | $223.72 | 2019-2023 | Xembify |
| Octapharma USA, INC. | $178.99 | 2021-2024 | Panzyga |
| Shire North American Group INC | $168.73 | 2019 | |
| Novartis Pharmaceuticals Corporation | $166.75 | 2019-2025 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biocryst US Sales Co., LLC | $113.82 | 2021-2022 | |
| Genentech USA, INC. | $109.89 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $98.41 | 2022 | |
| Blueprint Medicines Corporation | $76.63 | 2023 | Ayvakit |
| Ars Pharmaceuticals Operations, INC. | $49.95 | 2025 | Neffy |
| Optinose US, INC. | $48.69 | 2019-2022 | |
| Adma Biomanufacturing LLC | $39.89 | 2021 | |
| Amgen INC. | $30.40 | 2024-2025 | Tezspire |
| Sanofi-Aventis U.S. LLC | $27.47 | 2021 | |
| Biocryst Pharmaceuticals, INC. | $25.23 | 2020 | |
| Bio Products Laboratory USA, INC. | $24.82 | 2021 | |
| Lilly USA, LLC | $20.96 | 2025 | Ebglyss |
| Incyte Corporation | $15.19 | 2022 | |
| Galderma Laboratories, L.P. | $15.00 | 2025 | Nemluvio |
| Merck Sharp & Dohme LLC | $13.64 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stuart White listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.